Last reviewed · How we verify

NCT04132258: RIB18

"Clinical and Epidemiological Characteristics of Inflammatory Rhinitis in Patients on Biotherapies"

Completed Last updated 8 June 2021
What this trial tests

trial testing survey in Inflammatory Rhinitis in 356 participants. Completed in 19 June 2020.

Timeline
19 November 2019
Primary endpoint
19 June 2020
19 June 2020

Quick facts

Lead sponsorNantes University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment356
Start date19 November 2019
Primary completion19 June 2020
Estimated completion19 June 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Inflammatory Rhinitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Inflammatory rhinitis is a side effect observed in patients treated with biotherapies in the context of chronic bowel disease (IBD) or spondylartrhopathy (SPA). This damage is still poorly described in the literature. I The objective of this study is to study the associated characteristics of crustal rhinitis in a cohort of patients treated with biotherapy for chronic inflammatory disease (IBD, SPA, psoriasis).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of survey

Trials testing the same drug.

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04132258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing